Adil Mehmood Malik, Jehan Shah, Khan Issa, Ilyas Muhammad, Khan Usama, Ali Wajid
Urology, Institute of Kidney Diseases, Peshawar, PAK.
Urology, Maqsood Medical Complex (MMC) General Hospital, Peshawar, PAK.
Cureus. 2024 Aug 16;16(8):e67027. doi: 10.7759/cureus.67027. eCollection 2024 Aug.
Background Benign prostatic hyperplasia (BPH) is a prevalent condition that a large portion of the male population develops with aging, in which the prostate gland enlarges and results in urinary symptoms. Objective The objective of this article is to assess patient-reported outcomes (PRO) of medical management of benign prostate hyperplasia in terms of international prostate symptoms score (IPSS), BPH impact index (BPHII), and treatment satisfaction score (TSS). Methods This descriptive study included 114 patients who received medical management for BPH during the period 5 May 2021 till 30 December 2023, at the Department of Urology, Institute of Kidney Disease Peshawar. Patient-reported outcomes were measured in terms of IPSS, BPHII, and TSS. Readings were recorded at the start of treatment and at three months of treatment and then compared. Data was analyzed using SPSS v.25 (IBM Inc., Armonk, New York). Results The mean age of the patients was 64.33 ± 6.12 years. The mean prostate size was 77.35 ± 12.83 ml. Overall mean pre-treatment and post-treatment IPSS was 24.82 ± 4.90 versus 15.57 ± 5.15, respectively (p-value 0.00). Mean pre-treatment and post-treatment BPHII were 11.98 ± 1.02 and 7.12 ± 2.46, respectively (p-value 0.000). The overall mean treatment satisfaction score was 6.89 ± 1.44. Conclusion Medical management improved symptomatology in BPH patients. This study is a step in the direction of the development of larger and longer-term PRO studies in BPH management.
良性前列腺增生（BPH）是一种常见疾病，很大一部分男性人群会随着年龄增长而发病，其前列腺会增大并导致排尿症状。
本文旨在根据国际前列腺症状评分（IPSS）、BPH影响指数（BPHII）和治疗满意度评分（TSS）评估良性前列腺增生药物治疗的患者报告结局（PRO）。
这项描述性研究纳入了2021年5月5日至2023年12月31日期间在白沙瓦肾病研究所泌尿外科接受BPH药物治疗的114例患者。通过IPSS、BPHII和TSS来衡量患者报告结局。在治疗开始时和治疗三个月时记录读数，然后进行比较。使用SPSS v.25（IBM公司，纽约州阿蒙克）分析数据。
患者的平均年龄为64.33±6.12岁。平均前列腺体积为77.35±12.83毫升。总体治疗前和治疗后的IPSS平均值分别为24.82±4.90和15.57±5.15（p值0.00）。治疗前和治疗后的BPHII平均值分别为11.98±1.02和7.12±2.46（p值0.000）。总体平均治疗满意度评分为6.89±1.44。
药物治疗改善了BPH患者的症状。本研究朝着开展更大规模、更长期的BPH管理PRO研究迈出了一步。
